GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » Peter Lynch Fair Value

Actinogen Medical (ASX:ACW) Peter Lynch Fair Value : A$-0.06 (As of Apr. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Actinogen Medical's PEG is 1. Actinogen Medical's 5-Year TTM EBITDA Growth Rate is 9.62. Actinogen Medical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01. Therefore, the Peter Lynch Fair Value for today is A$-0.06.

As of today (2024-04-29), Actinogen Medical's share price is A$0.032. Actinogen Medical's Peter Lynch fair value is A$-0.06. Therefore, Actinogen Medical's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Actinogen Medical's Peter Lynch Fair Value or its related term are showing as below:



ASX:ACW's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.48
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Actinogen Medical Peter Lynch Fair Value Historical Data

The historical data trend for Actinogen Medical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical Peter Lynch Fair Value Chart

Actinogen Medical Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actinogen Medical Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actinogen Medical's Peter Lynch Fair Value

For the Biotechnology subindustry, Actinogen Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Price-to-Peter-Lynch-Fair-Value falls into.



Actinogen Medical Peter Lynch Fair Value Calculation

Actinogen Medical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 9.62 *-0.006
=-0.06

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Actinogen Medical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Actinogen Medical  (ASX:ACW) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 9.62 instead of 15 in this case.

Actinogen Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.032/-0.06
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinogen Medical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical (ASX:ACW) Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish 10-13-2014

Stocks That Are Making A Good Come Back

By reports.droy reports.droy 03-10-2015